Compare CYTK & DOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | DOX |
|---|---|---|
| Founded | 1997 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.5B |
| IPO Year | 2004 | 1998 |
| Metric | CYTK | DOX |
|---|---|---|
| Price | $68.45 | $76.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 3 |
| Target Price | $77.87 | ★ $97.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 11-05-2025 | 11-11-2025 |
| Dividend Yield | N/A | ★ 2.98% |
| EPS Growth | N/A | ★ 18.92 |
| EPS | N/A | ★ 5.05 |
| Revenue | $87,211,000.00 | ★ $4,532,913,000.00 |
| Revenue This Year | $363.61 | $5.03 |
| Revenue Next Year | $64.33 | $5.25 |
| P/E Ratio | ★ N/A | $15.14 |
| Revenue Growth | ★ 2609.26 | N/A |
| 52 Week Low | $29.31 | $74.32 |
| 52 Week High | $69.33 | $95.41 |
| Indicator | CYTK | DOX |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 38.04 |
| Support Level | $59.85 | $74.45 |
| Resistance Level | $67.98 | $76.35 |
| Average True Range (ATR) | 2.72 | 2.16 |
| MACD | 0.13 | -0.20 |
| Stochastic Oscillator | 91.35 | 18.48 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.